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Background: Gross cystic disease fluid protein 15 (GCDFP-15), which is regulated by the androgen receptor (AR), is
a diagnostic marker for mammary differentiation in histopathology. We determined the expression of GCDFP-15 in
breast cancer subtypes, its potential prognostic and predictive value, as well as its relationship to AR expression.
Methods: 602 pre-therapeutic breast cancer core biopsies from the phase III randomized neoadjuvant GeparTrio
trial (NCT00544765) were investigated for GCDFP-15 expression by immunohistochemistry. Expression data were
correlated with disease-free (DFS) and overall survival (OS) time as well as pathological complete response (pCR) to
neoadjuvant chemotherapy.
Results: 239 tumors (39.7%) were GCDFP-15 positive. GCDFP-15 expression was positively linked to hormone receptor
(HR) and HER2 positive tumor type, while most triple negative carcinomas were negative (p < 0.0001). GCDFP-15 was
also strongly correlated to AR expression (p 0.001), and to the so-called molecular apocrine subtype (HR-/AR+, p <
0.0001). Higher rates of GCDFP-15 positivity were seen in tumors of lower grade (<0.0001) and negative nodal status
(p = 0.008). GCDFP-15 positive tumors tended to have a more favourable prognosis than GCDFP-15 negative tumors
(DFS (p = 0.052) and OS (p = 0.044)), which was not independent from other factors in multivariate analysis. GCDFP-15
expression was not linked to pCR. Histological apocrine differentiation was frequent in molecular apocrine carcinomas
(60.7%), and was associated with GCDFP-15 within this group (p = 0.039).
Conclusions: GCDFP-15 expression is higher in tumors with favorable prognostic features. GCDFP-15 expression is
further a frequent feature of AR positive tumors and the molecular apocrine subtype. It might have reduced
sensitivity as a diagnostic marker for mammary differentiation in triple negative tumors as compared to HR or
HER2 positive tumor types.
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Gross cystic disease fluid protein 15 (GCDFP-15, syn.
prolactin-inducible protein, PIP) is a 15 kDa protein that
was originally detected in the cystic fluid from cystic
mastopathy [1]. It is not expressed in normal ductal or
lobular epithelium but in apocrine metaplasia of the
breast [2]. Apart from breast cancer, only very few tu-
mors, such as prostate cancer and carcinomas of the
skin appendages express GCDFP-15 [3]. It is therefore* Correspondence: silvia.darb-esfahani@charite.de
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article, unless otherwise stated.highly specific for mammary differentiation in females,
and is frequently used as an immunohistochemical marker
for the evaluation of a potential mammary origin of meta-
static carcinoma of unknown primary site. The expression
of GCDFP-15 is regulated by the androgen receptor (AR)
[4], however, little is known about its function. A recent
study on gene expression profiles in androgen-stimulated,
GDCFP-15 expressing versus GCDFP-15 non-expressing
breast cancer cell lines, reported an up-regulation of pro-
apoptotic and anti-proliferative genes along with GCDFP-
15 [5]. In carcinomas of the breast, GCDFP-15 is also used
as a marker for apocrine differentiation [2,6-9]. Apocrine
breast carcinoma is a rare subtype of invasive ductalentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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features such as abundant eosinophilic and granular cyto-
plasm, and shows frequent expression of the androgen
receptor (AR) [10]. Some years ago a so-called molecular
apocrine subset of breast carcinoma has been defined by
gene expression analysis, and was characterized by active
AR and weak or absent estrogen receptor (ER) signalling
[11]. In this study, all tumors that were assigned to the
molecular apocrine group had strong morphological fea-
tures of apocrine differentiation. The existence of the mo-
lecular apocrine subtype has since then been reproduced
[12,13]. However, its clinical impact is conflictive to date.
We used a large and well-characterized cohort of
breast cancer patients who underwent anthracycline/tax-
ane-based neoadjuvant chemotherapy (NACT) in the
phase III randomized GeparTrio trial (NCT00544765) to
investigate the distribution of GCDFP-15 expression in
biological subtypes of breast cancer, its potential prog-
nostic and predictive value, as well as its relationship to
AR expression. GCDFP-15 expression and biological
tumor types were determined by immunohistochemistry
in pre-therapeutic breast cancer core biopsies.
Methods
Study Population
Samples from the prospective neoadjuvant phase III
GeparTrio study (NCT00544765) and the GeparTrio
pilot study performed by the German Breast Group
(GBG), Neu-Isenburg, Germany were used. Patients were
treated with anthracycline/taxane-based NACT. The de-
tails of study setup and treatments have been published
before [14-17]. HER2 positive patients had not received
trastuzumab in GeparTrio as this was not the standard of
care during the study period. Baseline clinico-pathological
data as well as data on hormone receptor (HR) status were
extracted from the study databases. Centrally evaluated
data on HER2 expression (based on immunohistochemis-
try and silver-enhanced in situ hybridization according to
ASCO/CAP guidelines [18] were used, as HER2 determin-
ation was not yet fully established in all pathologic labora-
tories at the time the study was conducted. Grading and
histology were also centrally determined; local data on HR
expression were used and substituted with central data if
missing (central evaluation: Institute of Pathology, Charité
Berlin). Consistent with the current practise when the trial
was performed, HR positivity was defined as estrogen (ER)
or progesterone receptor (PR) expression in more than
10% of tumor cells. We also exploratorily applied the cut-
off of 1% currently recommended by ASCO/CAP [19]; use
of this definition of HR positivity yielded quite similar re-
sults (see results section). Data on AR expression had been
obtained from 545 cases in a previous study [20]. In brief,
AR staining intensity as well as percentage of stained
cells was multiplied to an immunoreactivity score (IRS),ranging from 0 (negative in all cells) to 12 (strongly
expressed in more than 80% of cells). Cases with an IRS
from 0–3 were scored as AR negative, opposed to cases
with an IRS of 4–12 (=AR positive). Definition of patho-
logical complete response (pCR) was complete absence of
invasive tumour cells in the breast and lymph nodes as
assessed at the time of surgery by the local pathologist
(ypT0/Tis; ypN0). Data on disease-free survival (DSF)
and overall survival (OS) were available for 570 patients,
with mean DFS of 3.08 years and mean OS of 3.42 years.
The baseline demographic and clinical characteristics of
the patients with tissue available for this translational
research project are shown in Table 1. The protocol was
reviewed and approved by all responsible ethics com-
mittees (Additional file 1: Table S1). All patients provided
written informed consent for anonymized subsequent
translational research.
Immunohistochemistry
Construction of a tissue micro array (TMA) of pre-
therapeutic core biopsies has been explained previously
[20]. Immunohistochemistry was performed on a Ventana
BenchMark XT instrument (Ventana Medical Systems
Inc., Tucson, AZ, USA) after pre-treatment with protease
using a mouse monoclonal antibody directed against
human GCDFP-15 (clone D6, dilution 1:400, Covance,
Princeton, NJ, USA). For visualization, the iView DAB
detection kit (Ventana Medical Systems Inc.) was used.
Stained slides were digitized and evaluated on the com-
puter monitor with support of the TMA Evaluator soft-
ware (VMScope GmbH, Berlin, Germany) by a board
certified pathologist (S. D.-E.). Both staining intensity and
the percentage of stained tumor cells were evaluated and
combined to an IRS (see previous chapter).
Statistical evaluation
Statistical analysis was performed using SPSS Statistics 19
(IBM Corporation, Somers, NY, USA). In logistic regres-
sion analyses, significance of the correlation with pCR was
assessed by the Wald test. Survival analyses were per-
formed with the Kaplan-Meier method and univariate log-
rank test and with Cox regression analysis for multivariate
tests. The association between GCDFP-15 expression and
clinico-pathological factors, biological tumor types, and
AR expression was analysed by Fisher’s exact test or Pear-
son’s chi square test, as indicated. All tests were two-sided,
and p-values <0.05 were considered as significant.
Results
GCDFP-15 expression pattern in human breast carcinomas
844 TMA spots were evaluated (one for each individual
tumor), whereas 203 spots contained no tumor cells
(24.1%), and 39 spots contained no tissue (4.6%), result-
ing in 602 informative cases (Figure 1). Consistent with
Table 1 Association of GCDFP-15 expression with baseline clinico-pathological parameters
Total (100%) GCDFP-15 negative GCDFP-15 positive p
Total 602 363 (60.3%) 239 (39.7%) -
HR (n = 576) 0.034a
Negative 175 116 (66.3%) 59 (33.7%)
Positive 401 228 (56.9%) 173 (43.1%)
HER2 (n = 576) 0.035a
Negative 478 299 (62.6%) 179 (37.4%)
Positive 116 60 (51.7%) 56 (48.3%)
Biological tumor types (n = 569) 0.001b
HR+/HER2- 328 189 (57.6%) 139 (42.4%)
HR+/HER+ 68 37 (54.4%) 31 (45.6%)
HR-/HER2+ 43 19 (44.2%) 24 (55.8%)
HR-/HER2- 130 96 (73.8%) 34 (26.2%)
AR (n = 545) <0.0001a
Negative 238 180 (75.6%) 58 (24.4%)
Positive 307 149 (48.5%) 158 (51.5%)
Age (n = 602) 0.066a
< 50 years 273 176 (64.5%) 97 (35.5%)
> = 50 years 329 187 (56.8%) 142 (43.2%)
Histological type (n = 602) 0.090b
Ductal/others 554 340 (61.4%) 214 (38.6%)
Lobular 48 23 (47.9%) 25 (52.1%)
Grading (n = 601) <0.0001a
G1-2 463 261 (56.4%) 202 (43.6%)
G3 138 102 (73.9%) 36 (26.1%)
cT (n = 591) 0.181a
cT1-2 395 230 (58.2%) 165 (41.8%)
cT3-4 196 126 (64.3%) 70 (35.7%)
cN (n = 583) 0.008a
cN0 261 141 (54.0%) 120 (46.0%)
cN+ 322 209 (64.9%) 113 (35.1%)
aFisher’s exact test.
bPearson’s chi square test.
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stricted to the cytoplasm of tumor cells. Positive tu-
mors mostly displayed a weak to moderate stain in
variable fractions of cells, and a patchy or mosaic-like
pattern could be frequently found (Figure 2A, B).
Sparse tumors showed diffuse staining (Figure 2C). In
the majority of samples however, GCDFP-15 expres-
sion was totally absent (n = 363 (60.3%, Figure 2D)).
We therefore decided to score each apparent staining
as positive and opposed it to totally lacking staining.
No GCDFP-15 staining was seen in non-epithelial cells
such as stromal or inflammatory cells.Association with biological tumor types and clinico-
pathological factors
GCDFP-15 expression was significantly enriched in tu-
mors with certain biological characteristics. There was a
modest increase of GDCFP-15 expression in HR and in
HER2 positive tumors (Table 1). GCDFP-15 positivity rate
was 43.1% in HR positive tumors and 33.7% in HR nega-
tive tumors (p = 0.034), and 48.3% HER2 positive carcin-
omas expressed GCDFP-15 as opposed to 37.4% HER2
negative tumors (p = 0.035). Consequently, GCDFP-15
was also differentially distributed among biological tumor
types, as defined by HR and HER2 status: frequency of
Figure 1 Consort diagram.
Figure 2 Immunohistochemical expression pattern of GCDFP-15 in breast cancer. A Tumor cells of an invasive lobular carcinoma, arranged
in indian file pattern and exhibiting moderate cytoplasmic staining for GDCFP-15 B Solid carcinoma nests with patchy, mosaic-like pattern of
GCDFP-15 expression C Diffuse GCDFP-15 expression in a poorly differentiated ductal carcinoma D Distribution of GCDFP-15 immunoreactivity
scores (IRS) in the study group. The majority of cases did not display any staining (IRS = 0); in the remaining carcinomas, IRS values were equally
distributed; the cut-off was set between IRS = 0 and IRS = 2.
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types (HR+/HER2-: 42.4%, HR+/HER2: 45.6%) as well in
HER2 positive tumors (HR-/HER2+: 55.8%) as opposed to
in triple negative breast carcinomas (TNBC, HR-/HER2-:
26.2%, p = 0.001, Table 1). Consistent with GCDFP-15 be-
ing a downstream target gene of AR [4], there was a
strong association between GCDFP-15 and AR expression.
51.5% of AR positive tumors were also positive for
GCDFP-15, whereas only 24% of AR negative carcin-
omas showed GCDFP-15 staining (p < 0.0001). As AR is
a frequent feature of apocrine tumor differentiation and
GCDFP-15 has also been proposed as a marker for apo-
crine differentiation, we tested GCDFP-15 expression
for an association with the so-called molecular apocrine
subtype (HR-/AR+), as described by Farmer et al. [11].
Tumor types according to Farmer were grouped as fol-
lows: HR + (AR+/−), n = 365), HR-/AR + (n = 56), and
HR-/AR- (n = 101). HER2 positivity was more frequent
in molecular apocrine carcinomas (42.9% as opposed to
17.1% in HR + (AR+/−) and 15.8% in HR-/AR-, p <
0.0001). There was a significant association between
GCDFP-15 and molecular apocrine subtype, with 67.9%
GCDFP-15 positive cases in this group (p < 0.0001).
41.6% of HR + (AR+/−) tumors were also positive for
GCDFP-15, while the rate of GCDFP-15 positive cases
in the subgroup that was completely negative for steroid
hormone receptors (HR-/AR-) with 18.8% was lower
than the one in triple negative tumors (HR-/HER2-,
26.2%, Table 1). GCDFP-15 was further associated with
certain favorable tumor features, such as lower tumor
grade (p < 0.0001), and negative nodal status (p = 0.008,
Table 1). Using the currently by ASCO/CAP guidelines [19]
recommended cutoff for ER/PR evaluation (<1% stained
tumor cells = negative, > = 1% stained tumor cells = posi-
tive) we obtained similar results: HR positivity rate in the
total study group was 79.5%, GCDFP-15 expression still
was associated with HR positivity (p = 0.046) and with mo-
lecular apocrine tumor type (p < 0.0001), although the rate
of molecular apocrine tumors was now decreased to 6.5%.
Morphological features of molecular apocrine carcinomas
We further wondered whether the molecular apocrine sub-
type was showed a distinct morphology and re-evaluated
hematoxylin/eosin-stained large sections of pre-therapeutic
core biopsies according to apocrine differentiation. Criteria
were based on Vranic et al. (2013) [6] and included tumors
with large nuclei and characteristic abundant eosinophilic
granular or foamy cytoplasm (type A, type B cells). Indeed,
molecular apocrine carcinomas were quite frequently of
apocrine phenotype (34/56, 60.7%, Figure 3A). Two carcin-
omas of pleomorphic lobular subtype, a poorly differenti-
ated subgroup of lobular-invasive carcinoma reported to
cluster with molecular apocrine tumors by gene expression
analysis [23], were among them (Figure 3B). Histologicallyapocrine carcinomas with HR-/AR + profile were
GCDFP-15 positive in most cases (27/34, 71.1%, p =
0.039; Figure 3A, B).
Prognostic impact of GCDFP-15 expression
GCDFP-15 expression was also studied for a potential
prognostic impact. GCDFP-15 positive tumors tended to
have a more favourable prognosis than GCDFP-15 nega-
tive tumors (DFS (p = 0.052) and OS (p = 0.044)) in the
study group (Figure 4A, B, Table 2). Explorative multi-
variate Cox regression analysis including HR and HER2
expression, age, nodal stage, and grading showed that
GCDFP-15 expression was not an independent prognos-
tic factor for OS (HR = 0.67, 95% CI = 0.37-1.20, p =
0.179, not shown). Similarly, GCDFP-15 was not a sig-
nificant prognostic marker for OS or DFS within the
biological tumor types (HR+/HER-, HR+/HER2+, HR-/
HER2+, HR-/HER2-) or in Farmer tumor types (HR +
(AR+/−), HR-/AR+, HR-/AR-; p < 0.05 for each test, not
shown). Farmer tumor types by themselves were also
prognostic for DSF and OS (log rank p = 0.024 for each),
however a survival difference was seen only between
HR- and HR + tumors, and was irrespective of an add-
itional AR expression (data not shown). The following
established prognostic makers for DFS and/or OS were
significant in univariate analysis in the GeparTrio cohort
as well: HR expression, biological tumor types, age,
tumor grade, cT, and cN (Table 2).
Predictive value of GCDFP-15 expression
We further evaluated if GCDFP-15 expression might have
predictive value for response to NACT and performed lo-
gistic regression analysis. In the total study group, there
was a non-significant trend towards a reduced probability
of pCR in GCDFP-15 positive tumors (pCR rate 21.2% vs
15.9%, OR = 0.70, 95% CI = 0.46-1.08, p = 0.106, Table 3).
GCDFP15 expression was not indicative of response to
NACT within biological tumor types or Farmer tumor
types (p < 0.05 for each test, not shown). Farmer tumor
types were significantly predictive for pCR, however simi-
larly to the survival analysis, only the HR status was rele-
vant for the predictive effect, and there was no difference
between molecular apocrine (HR-/AR+) and HR-/AR- tu-
mors: odds ratio (OR) of HR-/AR + 4.1 (95% CI 2.1-7.7),
pCR rate 33.9%; OR of HR-/AR- 4.2 (95% CI 2.5-7.1), pCR
rate 34.7%, as compared to HR+, respectively (p < 0.0001,
pCR rate 11.2%). Already known predictive factors were
also significant in our cohort: age, histological type, grade,
HR expression, HER2 expression, and biological tumor
types (Table 3).
Discussion
We investigated the expression of GCDFP-15 in a large
and well-characterized clinical trial cohort of breast
Figure 3 Morphology of molecular apocrine carcinomas. A Apocrine carcinoma with abundant eosinophilic granular cytoplasm exhibiting
diffuse GCDFP-15 expression (insert) B Pleomorphic lobular carcinoma with dyscohesive growth of large cells with highly atypical nuclei and
eosinophilic granular cytoplasm, strong diffuse GCDFP-15 expression is seen by immunohistochemistry (insert).
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on its distribution in breast cancer subtypes and its
prognostic impact. We found that GCDFP-15 was in-
creased in HR positive as well as in HER2 positive sub-
types as compared to TNBC (HR-/HER2-). GCDFP-15
expression was not predictive for response to NACT. Al-
though GCDFP-15 was a favorable prognostic factor for
DFS and OS in univariate analysis, this impact was not
independent from other factors and not evident within
breast cancers subtypes. GCDFP-15 was furthermoreFigure 4 Survival analysis A, B DFS and OS in dependence of GCDFP-strongly associated with AR and therefore enriched in
the so-called molecular apocrine breast cancer subtype.
Although widely used as a diagnostic marker for breast
carcinoma in pathology, the prognostic value of GCDFP-
15 has not been systematically evaluated to date. Pagani
(1994), in a small case series of 33 breast cancers found
evidence of a longer relapse-free survival in patients with
tumors positive for GCDFP15 gene expression [24].
Fritzsche et al. (2007) reported GCDFP-15 as a positive
prognostic factor in a cohort of 165 carcinomas [25].15 expression in the study group.
Table 2 Univariate survival analysis
DFS OS
% events Mean survival, years (SE) p % events Mean survival, years (SE) p
GCDFP-15 0.044
Negative 30.3 5.85 (0.24) 19.3 7.07 (0.23)
Positive 25.1 6.67 (0.30) 0.052 13.9 7.75 (0.27)
HR 0.013
Negative 35.6 5.53 (0.36) 23.3 6.75 (0.34)
Positive 25.0 6.48 (0.23) 0.004 19.3 7.67 (0.34)
HER2 0.686
Negative 26.3 6.31 (0.22) 16.0 7.46 (0.21)
Positive 37.0 5.64 (0.40) 0.114 22.3 7.06 (0.24)
Biological tumor types 0.084
HR+/HER2- 23.2 6.61 (0.25) 13.7 7.71 (0.24)
HR+/HER2+ 33.8 5.86 (0.52) 16.9 7.45 (0.43)
HR-/HER2+ 43.6 4.98 (0.60) 30.8 6.23 (0.53)
HR-/HER2- 33.3 5.59 (0.42) 0.011 21.1 6.86 (0.41)
Age 0.046
< 50 years 24.9 6.48 (0.28) 12.8 7.79 (0.25)
> = 50 years 31.0 5.93 (0.26) 0.120 20.8 7.06 (0.24)
Histological type 0.915
Ductal/others 28.8 6.15 (0.20) 17.2 7.40 (0.19)
Lobular 10.0 6.42 (0.55) 0.309 17.4 6.82 (0.55)
grading 0.043
G1-2 26.4 6.42 (0.22) 16.1 7.54 (0.20)
G3 34.6 5.35 (0.41) 0.005 20.8 6.70 (0.40)
cT 0.001
cT1-2 20.8 6.90 (0.24) 12.4 7.88 (0.22)
cT3-4 43.9 4.93 (0.31) <0.0001 26.7 6.65 (0.31)
cN <0.0001
cN0 22.4 6.91 (0.28) 11.4 8.12 (0.24)
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15 expression was not investigated for each biological
tumor type separately. Due to the very different molecular
biology of those breast cancer subtypes, biomarkers may
have quite varying prognostic implication within the sub-
types. We show here that the prognostic impact of
GCDFP-15 is most likely a bystander effect of its associ-
ation with other factors, such as HR expression, nodal
stage, and tumor grade. Our study thereby confirms previ-
ous findings of an association between GCDFP-15 expres-
sion and features of good-prognosis tumors [7,22,26], and
it might be speculated that GCDFP-15 parallels the ex-
pression of its regulatory factor AR, which is also linked tofavorable prognostic clinico-pathological features, as we
showed previously [20]. We further found that GCDFP-15
is differentially expressed in breast cancer subtypes and is
enriched in luminal and HER2 positive carcinomas, while
being relatively sparse in TNBC. Similarly, Huo et al.
(2013) reported a rather low percentage of GCDFP-15 pos-
itives in primary (14%) and metastatic TNBC (21%) [19].
Lewis et al. (2011) found even higher rates of GCDFP-15
expression than us in luminal (65-71%) and in HER2 posi-
tive carcinomas (64%), and found only one out 33 TNBC
(basal-like and unclassified triple negative tumors) to be
positive for GCDFP-15, however, their cohort being rela-
tively small, might have underestimated the frequency of
Table 3 Univariate logistic regression: association with pCR
n Events % pCR OR 95% CI p
GCDFP-15 0.106
Negative 363 77 21.2 1 -
Positive 239 38 15.9 0.70 0.46-1.08
HR <0.0001
Negative 175 61 34.9 1 -
Positive 401 45 11.2 0.24 0.15-0.37
HER2 <0.0001
Negative 478 77 16.1 1 -
Positive 116 36 31.0 2.34 1.48-3.72
Biological tumor types <0.0001
HR+/HER2- 328 28 8.5 1 -
HER2+ (HR+/−) 111 34 30.6 4.73 2.70-8.28
HR-/HER2- 130 43 33.1 5.30 3.11-0.02
Age 0.001
< 50 years 273 68 24.9 1 -
> = 50 years 329 47 14.3 0.50 0.33-0.76
Histological type
Ductal/others 554 113 20.4 1 -
Lobular 48 2 4.2 0.17 0.04-0.71
Grading <0.0001
G1-2 463 74 16.0 1 -
G3 138 41 29.7 2.22 1.43-3.46
cT 0.098
cT1-2 395 83 21.0 1 -
cT3-4 196 30 15.3 0.68 0.43-1.07
cN 0.809
cN0 261 49 18.8 1 -
cN+ 322 63 19.6 1.05 0.70-1.59
OR: Odd’s ratio.
CI: confidence interval.
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data warrant care if GCDFP-15 is used as a diagnostic
marker for mammary differentiation of metastases of a
cancer of unknown primary (CUP) because a significant
proportion of breast cancers, particularly TNBC might be
negative. An extended panel of immunohistochemical
markers for mammary differentiation should be used to in-
crease sensitivity. We show an enrichment of GCDFP15
expression in HER2 positive tumors and a strong associ-
ation with AR expression, and are therefore in line with
previous reports [7,22,27]. Not surprisingly, we further
found GCDFP-15 to be elevated in the so-called molecular
apocrine carcinomas that are defined by AR expression in
the absence of HR expression [11]. In our study histo-
logical apocrine differentiation was found in 60.7% of mo-
lecular apocrine carcinomas; additionally, GCDFP-15within the molecular apocrine subgroup was associated
with histological signs of apocrine differentiation, which
suggests that ER/PR, AR, and GCDFP-15 expression are
helpful markers to confirm apocrine differentiation in mor-
phologically conspicuous cases. On the other hand, 39.3%
of HR-/AR + carcinomas did not show apocrine morph-
ology in our cohort, which indicates that molecularly and
morphologically defined apocrine groups overlap only
partly. The clinical significance of the molecular apocrine
subtype is not clear to date and remains to be determined
as proposed by the current WHO Classification of Tumors
of the Breast [28] (2012), similarly conflictive data exist re-
garding the prognostic impact of histologically defined
apocrine subtype (reviewed by Vranic et al. [6]). Our study
does not point to a particular prognosis or therapy re-
sponse of HR-/AR + carcinomas, as pCR rate and survival
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AR expression. Interestingly, HER2 expression seems to
interact with AR in HR negative tumors in prognostic
terms, as in our previous study in the same cohort, AR
positivity was a positive prognostic factor only in the mo-
lecular subgroup of triple negative breast cancer (as de-
fined by ER/PR/HER2 negativity).
A limitation of our study is the reduced sample size in
the HER2 positive tumor types (HR+/HER2+: n = 68,
HR-/HER2+: n = 43), which might hamper the detection
of a differential expression of GCDFP-15 or a prognostic
impact of GCDFP-15 expression within those tumor types.
Furthermore, relatively short follow-up times indicate that
survival analysis should be interpreted cautiously (the
GeparTrio study not being powered for survival as a pri-
mary end point). An additional limitation might be that
we used a TMA constructed out of core biopsies, which in
some cases contained only few tumor cells and which to-
gether with the focal expression pattern of GCDFP-15
might result in a reduced sensitivity for detection of
GCDFP-15 expression in some tumors. However, the rate
of GCDFP-15 expression in our study group (39.7%) was
in the range reported in the literature [21,26]. Only 602
out of 2.357 patients in the original GeparTrio studies
could be included for this project; however this is still the
largest study on GCDFP-15 expression to date.
Conclusion
GCDFP-15 is expressed in all major biological breast cancer
subtypes, and may be particularly useful as a diagnostic
marker for mammary differentiation in HR and HER2 posi-
tive tumors, while there is reduced sensitivity in the triple
negative subset. Due to its strong link to AR expression it
may also be a marker for the so-called molecular apocrine
subtype. GCDFP-15 is linked to clinico-pathological factors
that indicate a better patient outcome, but is by itself no in-
dependent prognostic factor and is not predictive of re-
sponse to anthracycline/taxane-based NACT.
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